Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
In Reply: Type 2 diabetes prevention after acute pancreatitis.
Journal: Cleveland Clinic journal of medicine
Published: June 01, 2026
Gastrointestinal disorders in patients with diabetes mellitus: A practical guide for primary care.
Journal: Cleveland Clinic journal of medicine
Published: April 01, 2026
HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Showing 1-7 of 7
Last Updated: 09/26/2026